CJC-1295 With DAC vs Without DAC: Why the Difference Actually Matters

If you have spent any time reading peptide protocols, you have seen “CJC-1295” written two different ways: with DAC and without DAC. Vendors, forums, and even some papers blur the names. That is a problem, because these are not two strengths of the same compound. They are related GHRH analogs with fundamentally different pharmacokinetics, and they drive the GH/IGF-1 axis in different patterns.

This article sorts the naming mess, walks through the structural difference, and summarizes what human and animal research actually showed. Educational only — not medical advice, not dosing guidance.

First: Clean Up the Names

CJC-1295 (also called CJC-1295 DAC, CJC-1295 with DAC, or DAC:GRF) is the long-acting analog developed by ConjuChem. It is a modified form of GHRH(1-29) with a C-terminal Drug Affinity Complex that covalently binds serum albumin.

CJC-1295 without DAC is more accurately called Modified GRF (1-29) or Mod GRF 1-29. It shares the same tetrasubstituted GHRH(1-29) core (D-Ala2, Gln8, Ala15, Leu27) but lacks the maleimidopropionyl-lysine DAC extension.

Several papers and product labels incorrectly treat those names as synonyms. They are not. If a vial simply says “CJC-1295,” you need to know which molecule is inside before you can reason about half-life or stacking logic. For related context on how GHRH analogs sit next to GHRPs, see our Ipamorelin vs CJC-1295 overview and the sermorelin deep dive.

What Both Versions Share

Both molecules are analogs of the active 1-29 fragment of human GHRH (the same backbone family as sermorelin). They bind pituitary GHRH receptors on somatotrophs and stimulate endogenous GH synthesis and release. Neither is exogenous recombinant GH. Both preserve the requirement for an intact hypothalamic-pituitary axis.

The four amino-acid substitutions that define the “modified” GRF core improve resistance to enzymatic breakdown relative to native GHRH(1-29), especially dipeptidyl peptidase-IV (DPP-IV) cleavage at the N-terminus. That is why Mod GRF lasts longer than plain sermorelin even without DAC — still short by drug standards, but more workable than native GHRH’s minutes-long half-life.

What DAC Actually Does

The Drug Affinity Complex is a reactive maleimide group on a C-terminal lysine. After subcutaneous injection, it forms a covalent bond with the free thiol on cysteine-34 of circulating serum albumin.

Jetté and colleagues at ConjuChem described this bioconjugation strategy in Endocrinology in 2005. In rats, CJC-1295 remained detectable in plasma beyond 72 hours, and Western blot showed immunoreactive peptide riding the albumin band within 15 minutes of dosing and still present past 24 hours. The albumin conjugate retained GRF-receptor activity and acute GH-releasing effect, with a larger GH AUC than unmodified hGRF(1-29) over a two-hour window.

Albumin binding does three practical things:

1. Shields the peptide from rapid renal clearance and proteolysis
2. Creates a circulating reservoir that slowly presents active peptide to the pituitary
3. Extends half-life from under an hour into a multi-day range

That is the entire reason “with DAC” and “without DAC” feel like different drugs in research settings.

Human Pharmacokinetics: The Teichman Data

The landmark human evidence is Teichman et al., 2006, in the Journal of Clinical Endocrinology & Metabolism. Two randomized, placebo-controlled, double-blind ascending-dose studies in healthy adults (ages 21–61) tested subcutaneous CJC-1295 (the DAC form).

Key findings after a single injection:

• Mean plasma GH rose 2- to 10-fold for 6 days or more, dose-dependently
• Mean plasma IGF-1 rose roughly 1.5- to 3-fold for 9–11 days
• Estimated half-life of CJC-1295 was 5.8–8.1 days
• After multiple doses, mean IGF-1 stayed above baseline for up to 28 days
• No serious adverse reactions were reported in those short trials; tolerability was described as relatively good, especially at lower studied microgram-per-kilogram ranges

That profile is why the DAC version was explored as a less-frequent injectable for conditions where sustained GH-axis support was the goal. It is also why enthusiasts who care about physiologic pulse shape often prefer the non-DAC molecule instead.

A later analysis by Sackmann-Sala et al. (2009) confirmed that activating the GH/IGF-1 axis with CJC-1295 produced measurable shifts in the serum protein profile of healthy adults, consistent with genuine downstream endocrine activity rather than a lab curiosity.

Pulsatility: The Ionescu and Frohman Finding

A common assumption is that long-acting GHRH analogs flatten GH into a continuous drip. Ionescu and Frohman tested that directly in 2006 (JCEM). During continuous stimulation by CJC-1295, pulse frequency and pulse magnitude were largely preserved, but basal (trough) GH rose substantially — on the order of a multi-fold increase in trough levels in the studied cohorts — and mean GH and IGF-1 increased with that elevated floor.

So DAC does not erase pulsatility. It raises the trough and the mean while pulses continue on top. Whether that elevated floor is desirable depends on the research question. Exogenous GH replacement tends to suppress endogenous pulses entirely; CJC-1295 does not do that. Still, a higher basal GH/IGF-1 set point is not the same physiology as clean, short pulses stacked onto a low nighttime trough.

Mod GRF 1-29, by contrast, is cleared in roughly half an hour. Each administration produces a discrete GHRH-like signal and a short GH pulse, then levels fall. That is why it is almost always discussed alongside frequent dosing schedules and, commonly, co-administration with a GHRP such as ipamorelin.

Why Enthusiasts Stack Mod GRF With a GHRP

GHRH-receptor and ghrelin-receptor (GHS-R1a) pathways converge on the somatotroph but are not redundant. Combining a short-acting GHRH analog with a selective GHRP is a long-standing research pattern because dual-pathway stimulation can produce larger acute GH pulses than either class alone.

In that framework:

• Mod GRF 1-29 (no DAC) supplies a brief GHRH signal timed to the GHRP pulse
• Ipamorelin or similar GHRPs open the ghrelin-receptor gate without the cortisol/prolactin baggage of older GHRPs
• CJC-1295 with DAC is less often “pulse-stacked” in the same way because it is already providing multi-day GHRH tone; pairing logic, if any, is different

None of this is a recommendation. It is the mechanistic reason the community treats the two CJC labels as non-interchangeable when designing protocols.

Preclinical Support Beyond Healthy Adults

Alba et al. (2006) showed that once-daily CJC-1295 normalized growth and related parameters in GHRH-knockout mice — animals that otherwise lack endogenous GHRH drive. That matters conceptually: the analog can substitute for missing GHRH tone in a deficiency model, which helped justify clinical development for GH deficiency and related indications.

Development later reached phase 2 for lipodystrophy and GH-related uses, then stopped after a trial subject death that the attending physician judged most likely unrelated (asymptomatic coronary disease with plaque rupture). The program was discontinued as a precaution. CJC-1295 never received FDA approval as a finished drug. What remains in the public research and compounding conversation is built on the peer-reviewed PK/PD package above, not on a modern labeled product.

Practical Comparison

If your mental model is “mimic natural GH pulses,” the no-DAC molecule matches that story more closely. If the model is “raise and hold GH/IGF-1 exposure with fewer injections,” DAC is the molecule the clinical papers actually studied.

Quality and Labeling Reality Check

Because the names are confused in the market, certificate-of-analysis literacy matters. Confirm the exact identity (with or without the maleimidopropionyl-Lys extension), purity, and whether the vendor’s sequence matches Mod GRF versus true CJC-1295. Our guide to reading a peptide COA and the sourcing transparency page exist for that reason. Reconstitution math is the same class of problem as other lyophilized research peptides — use the reconstitution guide and calculator if you are working through units and BAC water, and compare market pricing on the price index.

Clinicians and patients navigating compounded GHRH analogs should also understand the 503A/503B landscape and, for an FDA-approved GHRH analog with a visceral-fat indication, the separate tesamorelin clinician guide.

Bottom Line

“CJC-1295” is not one thing. With DAC is a long-acting, albumin-binding GHRH analog with multi-day half-life and human data showing sustained GH and IGF-1 elevation plus preserved pulses on a higher trough. Without DAC (Mod GRF 1-29) is a short-acting modified GHRH fragment built for brief, stackable pulses. Confusing them leads to wrong expectations about frequency, IGF-1 kinetics, and how they combine with GHRPs.

Stay mechanism-first, demand clear labeling, and treat both as research/educational compounds unless they sit inside a legitimate clinical pathway. For providers and next steps, browse the directory or experts pages, and start from Peptides 101 if you are still mapping the broader landscape.